Overview

BioElectronics Corporation designs, develops, manufactures and markets a variety of proprietary, drug-free, anti-inflammatory patches for a broad range of medical indications. The Company's patch products, which are marketed under the trade name ActiPatch TherapyR, deliver pulsed electromagnetic field therapy, a clinically-proven and widely-accepted anti-inflammatory and pain relief therapy that, prior to the introduction of the Company's products, had only been offered through large office- or hospital-based equipment. The Company believes pulsed electromagnetic energy therapy will increasingly be used as an alternative or adjunct to many wound care procedures or therapies because it may relieve pain and swelling, shorten or halt the inflammatory phase, accelerate tissue healing, minimize the appearance of scars and increase the strength of regenerated tissue.

 

---

Investment Highlights

---

Profile

BioElectronics Corporation is the maker of Actipatch, a microchip embedded into a disposable soft foam patch that delivers pulsed electromagnetic field therapy, a clinically proven and widely accepted anti-inflammatory and pain relief therapy previously only available from large facility-based machines. The Actipatch is designed to meet the market demand for an effective, inexpensive, drug-free, therapeutic agent for the soft tissue injury market. In the US alone, there are an estimated 200+ million soft tissue injuries annually. The unique value proposition of ActiPatch™ is delivery of drug-free therapy that accelerates healing by 30 to 50% when compared with current standard methods of patient care.

ActiPatch ™ causes a reduction in the swelling (edema) and inflammation that occurs after tissue injury – a true and beneficial acceleration in the healing process. When soft tissue is damaged the cells separate to prevent the transmission of infection. The cells leak fluid and cellular components break down while the cellular debris causes inflammation, swelling and pain. ActiPatch ™ stabilizes the leaking cell membrane by, in effect, recharging the membrane. The pulsed energy delivered by ActiPatch ™ drives out the edematous fluid along with byproducts of the damaged tissue. The ActiPatch ™ creates an environment in which cell-to-cell communication is re-established in the area of the injured tissue. Inflammation is decreased and tissue repair begins. As a result of the decreased inflammation, a decrease in the pain associated with the soft tissue injury often occurs.

Market opportunities for the products are: Sprains/Sports Injuries, Wound Care, Post-Surgical, Fracture Management and Repetitive Stress Injuries.

Regulatory Milestones Achieved:
 

---

Strategic Marketing Relationships

BioElectronics signed an exclusive three-year supply and distribution agreement with Byron Medical, Inc. a subsidiary of Mentor Corporation (NYSE:MNT), a large supplier of medical products worldwide, to cover marketing of Actipatch ™ Therapy products to plastic surgeons worldwide.

In July 2005, BioElectronics announced an agreement with MaxMed Technologies, maker of the PedAlign ™ brand of custom orthotics products. The new wearable and disposable Actipatch ™ will be available as an insert into the PedAlign ™ product as a unique offering to providers that order PedAlign ™ custom orthotic products.
 

In November 2005, BioElectronics announced a partnership with PROFOOT, Inc. for distribution of the Actipatch ™ product in Canada. The product will be available at prominent retail stores throughout Canada. PROFOOT Inc. is America’s second largest brand of consumer foot care products and the brand is available at tens of thousands of mass-retail outlets in Canada, the US and 20 other countries.
 

Bioelectronics has also entered into a distribution agreement with Virginia-based Medical Sales Professionals, Inc (MSP). MSP sells and distributes medical supplies to professional and college sports teams and health care providers. Currently, Actipatch ™ is in use by 14 professional sports teams.

---

 

Medical Treatments

To date, the Company has focused its product development efforts on the plastic surgery, podiatry and wound care markets, and has established a new-product pipeline that includes products for the treatment of the following medical indications:

Repetitive Stress Injuries

Plastic and Cosmetic Surgery

Chronic Wounds
 

Sprains
 

Ankle
 

---

Product Information

ActiPatch™

The ActiPatch™ is a medical devices which deliver pulsed electromagnetic frequency (PEMF) therapies to accelerate healing of soft tissue injuries. A reduction of pain and swelling allows patients to return to normal activities much sooner. Patented technology based on clinically proven, widely accepted PEMF therapy.

The Company's first product, ActiPatch is A Drug-Free Painless Pulsed Energy Patch. The FDA has cleared ActiPatch for the treatment of edema following blepharoplasty.

The ActiPatch™ delivers a solution that is:

Actually the benefits of pulsed electromagnetic field therapy have been clinically accepted for many years. What is new is that the company's has made it smaller, virtually weightless and inexpensive. ActiPatch is "wearable" technology that delivers freedom from discomfort after surgery, allowing the user to quickly return to your active life.

A surgeon possesses extraordinary skills and advanced techniques, but any surgical procedure will result in temporary damage to tissue cells. The users body naturally responds with a period of bruising, swelling and pain. Unlike conventional remedies which simply mask the discomfort of inflammation by means of pain suppressing medications, ActiPatch relieves symptoms naturally by treating the cellular source of edema and helping the body to remove inflammatory fluids. The effectiveness of ActiPatch therapy has been consistently proven in clinical trials to result in less swelling, less bruising and a shorter, less painful recovery period.

The ActiPatch device is flexible, light weight and easy to apply and use. Once activated, ActiPatch begins pulsing a continuous low level current to energize damaged cells in the surgical region, helping remove the effects of trauma so you can feel better and look better faster than you would have thought possible.

Benefits

 

---

Recent News and Press Releases

BioElectronics Corporation Finalizes Design for New Retail Footcare Product in Partnership With ProFoot(TM) for the Canadian Retail Market (June 6, 2006)

Thomas O'Connor, Executive VP of Operations, COO and CFO of BioElectronics, is Featured in an Audio Interview at SmallCapVoice.com (May 18, 2006)
 

BioElectronics Corporation Announces New 510(k) Market Clearance Application Filed With FDA (May 16, 2006)
 

BioElectronics Corporation Announces the Addition of Dr. Michael Fox as a Consulting Podiatrist (May 9, 2006)
 

BioElectronics Corporation Announces the Addition of Dr. Michael Z. Metzger as a Consulting Podiatrist (April 25, 2006)
 

BioElectronics Corporation Names Tim Bream of the Chicago Bears to Sports Medicine Council (April 12, 2006)
 

BioElectronics Corporation Announces Development of New Sports Medicine Products (April 4, 2006)
 

BioElectronics Corporation Announces Introduction of Its Pulsed Electromagnetic Therapy in Podiatry Education Program (March 28, 2006)
 

BioElectronics Corporation Announces Agreement with the Lahey Clinic for ActiPatch Clinical Studies (March 21, 2006)
 

BioElectronics Corporation Launches Clinical Trials for Heel Pain (March 15, 2006)
 

---

Management Team

Andrew J. Whelan
President and Chief Executive Officer, and Chairman

Mr. Whelan is a seasoned business executive with a strong financial, consulting, and management background. He was a founder, Chairman, and President of Physicians' Pharmaceutical Services, Inc., a public company, and a charter member of the Maryland Chapter of Inc's Fastest Growing Companies in America. Mr. Whelan was also a founder, President, and CEO of Drug Counters, a chain of managed care retail pharmacies, which was sold to Diagnostek, Inc.

 

Thomas J. O'Connor
Vice President, Operations, Chief Financial Officer, Secretary & Director

Mr. O'Connor has served as Vice President Operations, Chief Financial Officer, Secretary and as a director of the Company since October 8, 2004. Mr. O'Connor received his bachelor of arts and masters of business administration and finance from Arizona State University. Mr. O'Connor served as Chief Operating Officer of the start-up team recruited in 1994 to develop CVS Corporation's prescription benefits management subsidiary and bring it to its current $2.0 billion per year revenue status. Prior to joining CVS, Mr. O'Connor held progressive positions in finance, systems development and marketing at PCS Health Systems. Additionally, Mr. O'Connor served as an independent consultant providing his e-health, emarketing, product development and marketing expertise to such clients as WebMD Corporation, Healtheon, Inc., ComCoTec, Inc. and Pharmaceutical Care Network

Joe Iglesias
Vice President Design and Engineering

Joe brings over fifteen years of product design, engineering and management experience in medical devices. He is a specialist in bioengineering and ergonomic design. Joe has designed and developed more than 20 innovative products in the fields of orthopedics, sports medicine, podiatry, chronic wound care and rehabilitation that have resulted in more than 25 patents in the US and worldwide. Joe received his BSME from University of California at Santa Barbara. Formerly, Joe was the Manager of Product Design for Royce Medical.

Wayne Gillis
International Business Development

Mr. Gillis has over twenty years of experience in the investment field. He is President and founder of Sherwood Financial Corp., which specializes in offshore investments and raising capital for startup firms in the technology sector. He also has an extensive background in the single-payer Health Care environments and has worked on projects with IBM and a number of pharmaceutical firms. He was educated at Dalhousie University, Bachelor of Commerce, Saint Mary's University, Bachelor of Science, Engineering, and NSCAD Industrial Design.

---

Contacts

Headquarters
Andrew J. Whelan, CEO
401 Rosemont Ave
3rd Floor Rosenstock Hall
Frederick, MD 21701
Phone: 301-644-3906
Fax: 301-644-3939
E- mail: info@actipatch.net

Sales & Marketing
BioElectronics Corporation
Dora Yoshimoto
31255 Cedar Valley Drive
Westlake, CA. 91361
Phone:866-757-ACTI (2284)
Fax:805-277-8041
E-mail: sales@bioelectronicscorp.com

---

 

 

 

 

 

FORWARD LOOKING STATEMENTS

This report includes forward-looking statements that reflect BioElectronics Corp. current expectations about its future results, performance, prospects and opportunities. BioElectronics Corp. has tried to identify these forward-looking statements by using words and phrases such as "may," "will," "expects," "anticipates," "believes," "intends," "estimates," "plan," "should," "typical," "preliminary," "we are confident" or similar expressions. These forward-looking statements are based on information currently available and are subject to a number of risks, uncertainties and other factors that could cause BioElectronics Corp.'s actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These risks, uncertainties and other factors include, without limitation, the Company's growth expectations and ongoing funding requirements, and specifically, the Company's growth prospects with scalable customers, and those outlined above. Other risks include the Company's limited operating history, the Company's history of operating losses, consumers' acceptance, the Company's use of licensed technologies, risk of increased competition, the potential need for additional financing, the terms and conditions of any financing that is consummated, the limited trading market for the Company's securities, the possible volatility of the Company's stock price, the concentration of ownership, and the potential fluctuation in the Company's operating results.

---

Disclaimer

AllPennyStocks.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. This is an advertisement for BioElectronics Corp. The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

© 1999-2006 AllPennyStocks.com. All rights reserved. AllPennyStocks.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. AllPennyStocks.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), AllPennyStocks.com will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the AllPennyStocks.com web site. AllPennyStocks.com has been compensated five thousand dollars by a non-affiliated third-party, SmallCapVoice.com for its efforts in presenting the BIEL profile on its web site and distributing it to its database of subscribers as well as other services. AllPennyStocks.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. As of the profile date, no shares have been sold. Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “expects’”, “will,” “anticipates,” “estimates, “believes,” or that by statements indicating certain actions “may,” “could,” or “might” occur.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.